<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803422</url>
  </required_header>
  <id_info>
    <org_study_id>P-2021-27</org_study_id>
    <nct_id>NCT04803422</nct_id>
  </id_info>
  <brief_title>Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.</brief_title>
  <acronym>PIPA</acronym>
  <official_title>Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis: A Cluster Randomized Cluster Crossover Non-Inferiority Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PIPA trial is a prospective, multicentre, cluster randomized cluster crossover&#xD;
      non-inferiority study. We aim to test whether a three-day postoperative course of per oral&#xD;
      antibiotics is non-inferior to a three-day postoperative course of intravenous antibiotics as&#xD;
      standard care after laparoscopic surgery for complicated appendicitis in regards to the risk&#xD;
      of postoperative intraabdominal abscess formation within 30-days&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complicated appendicitis increases the risk of postoperative intra-abdominal abscess.&#xD;
      Treatment of complicated appendicitis are usually with a postoperative course of intravenous&#xD;
      antibiotics. There is need for a study confirming the results of retrospective studies&#xD;
      showing that a postoperative course of oral antibiotics is not inferior to intravenous&#xD;
      antibiotics after laparoscopic surgery for complicated appendicitis.&#xD;
&#xD;
      The PIPA trial will be a prospective, multicenter, cluster randomized cluster crossover&#xD;
      non-inferiority study designed to test whether a three-day postoperative course of per oral&#xD;
      antibiotics is non-inferior to a three-day postoperative course of intravenous antibiotics as&#xD;
      standard care after laparoscopic surgery for complicated appendicitis in regards to the risk&#xD;
      of postoperative intraabdominal abscess formation within 30-days. Participating hospitals&#xD;
      will be randomized to either a 6-month period with a per oral antibiotic regime followed by a&#xD;
      6-month period with an intravenous antibiotic regime, or 6-month period with an intravenous&#xD;
      antibiotic regime followed by a 6-month period with a per oral antibiotic regime for the&#xD;
      postoperative treatment after laparoscopic surgery for complicated appendicitis. Primary&#xD;
      outcome will be the incidence of intra-abdominal abscess by the postoperative day 30.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>An electronic randomization sequence in the program R will be applied to randomize centers (clusters) 1:1. After randomization the allocation will not be concealed</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-abdominal abscess</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>Primary outcome is defined as an imaging verified intraabdominal mass treated with drainage or antibiotics, or a surgically verified intra-abdominal abscess</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative stay</measure>
    <time_frame>The event is assessed at postoperative day 30. The event is determnied beginning from the time the surgery ends till the time the patient is discharged from the hospital.</time_frame>
    <description>postoperative length of stay measured in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications according to Clavien-Dindo Classifcation</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>complications according to the Clavien-Dindo classification at postoperative day 30, that require in- or outpatient treatment, complications grade ≥3a according to Clavien-Dindo Classification at postoperative day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>Assessed at postoperative day 30. Data for both in- and outpatient costs will be extracted from the Danish Health Authority</time_frame>
    <description>In- and outpatient costs and overall costs of both in-and- outpatient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound infection</measure>
    <time_frame>Assessed postoperative day 30</time_frame>
    <description>Postoperative wound infection that require in-and - outpatient treatment. A wound infection is defined as a clinically suspected wound infection which has been treated with an opening of the wound or where antibiotics has been administered for this indication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2631</enrollment>
  <condition>Complicated Appendicitis</condition>
  <arm_group>
    <arm_group_label>Arm 1- Postoperative Course</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.&#xD;
First 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin.&#xD;
Last 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Postoperative Course</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim.&#xD;
First 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim.&#xD;
Last 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic</intervention_name>
    <description>The study aims to test whether oral antibiotics is non-inferior compared to intravenous antibiotics.</description>
    <arm_group_label>Arm 1- Postoperative Course</arm_group_label>
    <arm_group_label>Arm 2 - Postoperative Course</arm_group_label>
    <other_name>metronidazole intravenous</other_name>
    <other_name>metronidazole oral</other_name>
    <other_name>Piperacillin / Tazobactam</other_name>
    <other_name>Amoxicillin / Clavulanic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  On cluster level, hospitals with emergency surgical admissions performing laparoscopic&#xD;
             appendectomies are eligible for inclusion.&#xD;
&#xD;
          -  On an individual level, participants are eligible for inclusion if they undergo a&#xD;
             laparoscopic appendectomy for appendicitis (both uncomplicated and complicated), are ≥&#xD;
             18 years of age, and provide a signed written consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria are specifically related to the therapy and individual participants&#xD;
             will be excluded if they undergo any other procedures than laparoscopic appendectomy&#xD;
             during index surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Abdirahman Mohamud, MD</last_name>
    <phone>+45 23485194</phone>
    <email>ahmm@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jakob Kleif, MD, PhD</last_name>
    <email>jakobkleif@icloud.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Slagelse Hospital, Department of Surgery</name>
      <address>
        <city>Slagelse</city>
        <zip>4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>23485194</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 27, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Appendicitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

